Skip to Content
MilliporeSigma
All Photos(2)

Documents

917796

Sigma-Aldrich

NanoFabTx PEG-PLGA drug formulation screening kit

for synthesis of PEGylated nanoparticles

Synonym(s):

NanoFabTx reagent kit, PEG-PLGA nanoparticles

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
NACRES:
NA.23

description

Drug loading screening kit, for synthesis of PEGylated PLGA nanoparticles
Kit components :
PEGPLGA-50L(912808-500mg)
PEGPLGA-75L(913049-500mg)
PEGPLGA-50H (915955-500mg)
PEGPLGA-75H (915718-500mg)
Stabilizer-Nano (907766-5g)

Quality Level

application(s)

advanced drug delivery

storage temp.

2-8°C

General description

NanoFabTx PEG-PLGA drug loading screening kit is a ready-to-use nanoformulation kit for the synthesis of PEGylated PLGA nanoparticles 50 nm to 350 nm in size. This kit provides properly selected PEGylated PLGAs, stabilizer, and formulation protocols for synthesis by nanoprecipitation and microfluidic methods. Four different PEGylated PLGAs are included in this kit, allowing rapid screening of optimal materials for enhancing drug loading. Protocols for two different particle synthesis methods are included.
  • A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
  • A Microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol uses NanoFabTx device kits (911593), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Application

NanoFabTx nanoformulation reagent kits enable users to encapsulate a wide variety of therapeutic drug molecules in PEGylated PLGA nanocarriers for targeted or sustained drug delivery without the need for lengthy trial-and-error optimization. PEGylated PLGAs are well suited towards applications involving sustained release because PEGylation has been shown to improve the circulation half-life of polymeric nanocarriers by altering the solubility and shielding the nanocarrier from enzymes and antibodies that may induce degradation, secretion, and clearance. Because poly(lactic-co-glycolic acid) (PLGA) is a biocompatible and biodegradable polymer approved by the FDA for biomedical and pharmaceutical applications, PLGA-based nanoparticles synthesized with the NanoFabTx kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.

Features and Benefits

  • Requires minimal laboratory setup
  • Optimized protocols with step-by-step instructions for either nanoprecipitation or microfluidics-based synthesis
  • Yields specifically sized, low polydispersity biodegradable, PEGylated PLGA nanoparticles from 50 nm to 350 nm in size
  • Maximizes the encapsulation of hydrophobic drugs
  • Four different PEGylated PLGAs are included

Legal Information

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

wgk_germany

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Susanne Schöttler et al.
Nature nanotechnology, 11(4), 372-377 (2016-02-16)
The current gold standard to reduce non-specific cellular uptake of drug delivery vehicles is by covalent attachment of poly(ethylene glycol) (PEG). It is thought that PEG can reduce protein adsorption and thereby confer a stealth effect. Here, we show that
Hassan A Almoustafa et al.
International journal of pharmaceutics, 533(1), 275-284 (2017-09-26)
Nanoprecipitation is a simple and increasingly trending method for nanoparticles preparation. The self-assembly feature of poly (ethylene glycol)-poly (lactide-co-glycolic acid) (PEG-PLGA) amphiphilic copolymer into a nanoparticle and its versatile structure makes nanoprecipitation one of the best methods for its preparation.
Y Li et al.
Journal of controlled release : official journal of the Controlled Release Society, 71(2), 203-211 (2001-03-29)
The aim of the present work was to assess the merits of PEGylated poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles as protein and peptide drugs (PPD) carriers. PEG-PLGA copolymer, which could be used to prepare the stealth nanoparticles or long-circulating nanoparticles, was synthesized
L Martin-Banderas et al.
Mini reviews in medicinal chemistry, 13(1), 58-69 (2012-09-15)
This article presents the potential of PLGA nanoparticles for the oral administration of drugs. Different strategies are used to improve oral absorption of these nanoparticles. These strategies are based on modification of nanoparticle surface properties. They can be achieved either
Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin V P, et al.
Advanced Drug Delivery Reviews, 16, 141-155 (1995)

Articles

Our NanoFabTx™ platform helps accelerate your drug development by providing ready-to-use formulations and microfluidic devices for reproducible synthesis of nano- to micro-sized particles and liposomes.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service